| Chiu SJ |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=5.690 ------>paper_class3=2 ------>paper_class2=1 ------>vol=97 ------>confirm_bywho=None ------>insert_bywho=sjchiu ------>Jurnal_Rank=6.9 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=369 ------>medlineContent= ------>unit=000 ------>insert_date=20060321 ------>iam=1 ------>update_date=None ------>author=??? ------>change_event=2 ------>ISSN=0168-3659 ------>authors_c= ------>score=461 ------>journal_name=Journal of controlled release ------>paper_name=Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®,) conjugated polyethylenimine ------>confirm_date=None ------>tch_id=094123 ------>pmid=15196762 ------>page1=357 ------>fullAbstract=A series of novel nonviral vectors targeting the HER-2/neu gene product human epidermal growth factor receptor-2 (HER2) were constructed and evaluated in breast cancer cell lines to optimize vector formulation for receptor-specific gene transfer. These vectors were DNA/polycation complexes (polyplexes) prepared by mixing, at varying ratios, plasmid DNA carrying a luciferase reporter gene to HerPEI, which is a conjugate of linear polyethylenimine (PEI), a cationic polymer, and trastuzumab (Herceptin), a HER2-specific monoclonal antibody. Transfection studies were carried out in both HER2 overexpressing Sk-Br-3 and HER2 low-expressing MDA-MB-231 breast cancer cells. The HerPEI polyplexes showed significantly greater transfection activity up to 20-folds than nonderivatized PEI-based polyplexes in the Sk-Br-3 cells. The transfection efficiency of targeted polyplexes was dependent on the trastuzumab:PEI ratio and can be blocked by excess free trastuzumab, suggesting HER2-mediated gene delivery. In contrast, no significant difference in transfection activities was observed between HER2-targeted and nontargeted polyplexes in the HER2 low-expressing MDA-MB-231 cells. The transfection efficiency of HerPEI polyplexes was retained in serum-containing medium. In summary, HerPEI polyplexes have shown promising HER2 receptor-specific gene transfer properties and warrant further evaluation as a tumor-targeted vector for gene therapy. ------>tmu_sno=None ------>sno=13175 ------>authors2=Ueno NT ------>authors3=Lee RJ ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Chiu SJ ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2004 ------>submit_flag=None ------>publish_month=6 |